LS
VRTX icon

Livforsakringsbolaget Skandia’s Vertex Pharmaceuticals VRTX Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$839K Hold
1,880
– – 0.03% 174
2025
Q4 		$852K Hold
1,880
– – 0.03% 188
2025
Q3 		$736K Hold
1,880
– – 0.03% 203
2025
Q2 		$837K Sell
1,880
-25,740
-93% -$11.9M 0.04% 202
2025
Q1 		$13.4M Sell
27,620
-200
-0.7% -$93.2K 0.76% 29
2024
Q4 		$11.2M Buy
27,820
+25,640
+1,176% +$11.9M 0.59% 33
2024
Q3 		$1.01M Sell
2,180
-19,685
-90% -$9.46M 0.05% 199
2024
Q2 		$10.2M Sell
21,865
-200
-0.9% -$86.8K 0.84% 25
2024
Q1 		$9.22M Hold
22,065
– – 0.78% 28
2023
Q4 		$8.98M Buy
22,065
+258
+1% +$95.3K 0.86% 23
2023
Q3 		$7.58M Buy
21,807
+4,620
+27% +$1.62M 0.83% 25
2023
Q2 		$6.05M Sell
17,187
-1,700
-9% -$573K 0.63% 46
2023
Q1 		$5.94M Buy
18,887
+3,100
+20% +$930K 0.62% 44
2022
Q4 		$4.56M Hold
15,787
– – 0.52% 55
2022
Q3 		$4.57M Sell
15,787
-2,500
-14% -$719K 0.56% 46
2022
Q2 		$5.15M Sell
18,287
-600
-3% -$161K 0.45% 55
2022
Q1 		$4.93M Buy
18,887
+3,500
+23% +$831K 0.33% 74
2021
Q4 		$3.38M Sell
15,387
-1,500
-9% -$292K 0.21% 108
2021
Q3 		$3.06M Sell
16,887
-400
-2% -$78.1K 0.19% 116
2021
Q2 		$3.48M Buy
17,287
+1,100
+7% +$230K 0.21% 104
2021
Q1 		$3.48M Buy
16,187
+1,900
+13% +$417K 0.24% 96
2020
Q4 		$3.38M Buy
14,287
+3,000
+27% +$688K 0.29% 76
2020
Q3 		$3.07M Buy
11,287
+2,170
+24% +$599K 0.33% 72
2020
Q2 		$2.65M Hold
9,117
– – 0.3% 77
2020
Q1 		$2.17M Buy
9,117
+900
+11% +$206K 0.31% 80
2019
Q4 		$1.8M Sell
8,217
-900
-10% -$182K 0.21% 117
2019
Q3 		$1.54M Hold
9,117
– – 0.18% 126
2019
Q2 		$1.67M Buy
9,117
+300
+3% +$52.4K 0.21% 117
2019
Q1 		$1.62M Buy
8,817
+6,550
+289% +$1.21M 0.21% 116
2018
Q4 		$376K Hold
2,267
– – 0.06% 248
2018
Q3 		$437K Sell
2,267
-2,300
-50% -$410K 0.05% 272
2018
Q2 		$776K Buy
4,567
+700
+18% +$109K 0.07% 242
2018
Q1 		$630K Hold
3,867
– – 0.06% 271
2017
Q4 		$580K Sell
3,867
-900
-19% -$133K 0.06% 294
2017
Q3 		$725K Hold
4,767
– – 0.06% 277
2017
Q2 		$614K Hold
4,767
– – 0.06% 302
2017
Q1 		$521K Sell
4,767
-7,700
-62% -$678K 0.05% 323
2016
Q4 		$918 Sell
12,467
-8,800
-41% -$716K 0.05% 386
2016
Q3 		$1.85M Hold
21,267
– – 0.09% 298
2016
Q2 		$1.83M Hold
21,267
– – 0.08% 283
2016
Q1 		$1.69M Hold
21,267
– – 0.08% 274
2015
Q4 		$2.68M Sell
21,267
-4,100
-16% -$495K 0.13% 171
2015
Q3 		$2.64M Hold
25,367
– – 0.14% 152
2015
Q2 		$3.13M Hold
25,367
– – 0.15% 139
2015
Q1 		$2.99M Sell
25,367
-1,200
-5% -$144K 0.15% 143
2014
Q4 		$3.16M Sell
26,567
-6,900
-21% -$777K 0.15% 154
2014
Q3 		$3.76M Hold
33,467
– – 0.14% 164
2014
Q2 		$3.17M Hold
33,467
– – 0.11% 201
2014
Q1 		$2.37M Buy
+33,467
New +$2.65M 0.09% 254

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Livforsakringsbolaget Skandia's VRTX Position: Q1 2026 in Review

Livforsakringsbolaget Skandia held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 1,880 shares worth $839K. The position accounts for 0.03% of the portfolio, ranked #174.

Livforsakringsbolaget Skandia first reported a position in VRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $13.4M in Q1 2025. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Livforsakringsbolaget Skandia held 1,880 shares of Vertex Pharmaceuticals worth $839K as of Q1 2026.
  • Livforsakringsbolaget Skandia left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.03% of Livforsakringsbolaget Skandia's portfolio in Q1 2026, its #174 holding.
  • Livforsakringsbolaget Skandia first reported a position in Vertex Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
  • Livforsakringsbolaget Skandia's Vertex Pharmaceuticals position peaked at $13.4M in Q1 2025.
  • 1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.